Pantop%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520d

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme system in gastric parietal cells. ## Primary Indications * Gastroesophageal reflux disease (GERD) * Erosive esophagitis healing and maintenance * Zollinger-Ellison syndrome * Adjunct to *Helicobacter pylori* eradication ## Adult Dosing * **GERD & Erosive Esophagitis Healing:** 40 mg orally once daily for 4-8 weeks. * **Erosive Esophagitis Maintenance:** 20 mg orally once daily. Some patients may require 40 mg daily. * **Zollinger-Ellison Syndrome:** Start with 40 mg orally twice daily. Doses may be adjusted based on gastric acid output. Typical doses range from 40 mg twice daily to 240 mg daily. * ***H. pylori* Eradication (in combination therapy):** 40 mg orally twice daily for 7-14 days. * **IV Administration:** * **GERD, Erosive Esophagitis, Ulcer Healing:** 40 mg IV once daily. * **Zollinger-Ellison Syndrome:** 40 mg IV twice daily. May increase to 80 mg IV every 24 hours. * **Continuous Infusion for GI Bleeding Prophylaxis/Treatment:** 80 mg IV bolus over 30 minutes, followed by a continuous infusion of 8 mg/hour. ## Pediatric Dosing Dosing in pediatric patients is less established and often relies on weight-based calculations and clinical judgment. Consult specific pediatric guidelines or institutional protocols. * **GERD (Age 5 years and older):** * **Healing of Erosive Esophagitis:** 20-40 mg orally once daily for up to 8 weeks. * **Maintenance of Healing:** 20 mg orally once daily. * **IV Administration (Age 5 years and older):** * **Healing of Erosive Esophagitis:** 40 mg IV once daily for up to 8 weeks. ## Dose Adjustments No dose adjustment is generally required for hepatic or renal impairment in oral formulations. For IV formulations, caution is advised in severe hepatic impairment. ## Contraindications * Known hypersensitivity to pantoprazole or any component of the formulation. * Concurrent use with rilpivirine-containing products. ## Adverse Effects Common: Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness. Less Common/Serious: * **_Clostridioides difficile_-associated diarrhea (CDAD)** * **Bone fracture** (hip, wrist, spine) - risk increases with prolonged use and higher doses. * **Hypomagnesemia** - can be serious and symptomatic (e.g., tetany, arrhythmias). * **Vitamin B12 deficiency** - due to prolonged acid suppression. * **Systemic Lupus Erythematosus (SLE)** - new onset or exacerbation. * **Fundic gland polyps** ## Key Drug Interactions * **Drugs requiring gastric acid for absorption:** Ketoconazole, itraconazole, posaconazole, iron salts, vitamin B12, erlotinib, gefitinib. Pantoprazole can decrease absorption. * **CYP2C19 Substrates:** Fluconazole may increase pantoprazole levels. Voriconazole may increase pantoprazole levels. Clopidogrel may have decreased antiplatelet activity (though clinical significance is debated). * **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. * **Rilpivirine:** Coadministration is contraindicated due to risk of decreased rilpivirine plasma concentrations and loss of virologic response. * **Sucralfate:** May delay absorption of PPIs; administer at least 30 minutes before sucralfate. ## Monitoring * Monitor for signs and symptoms of hypomagnesemia (e.g., muscle spasms, seizures, tremors, arrhythmias). * Monitor for signs of vitamin B12 deficiency with prolonged therapy. * Monitor for signs of _Clostridioides difficile_-associated diarrhea. * Consider bone mineral density monitoring in patients at risk for osteoporosis. * For Zollinger-Ellison syndrome, monitor gastric acid output. ## Clinical Pearls * Pantoprazole is available in both oral (delayed-release tablets, granules for oral suspension) and intravenous formulations. * IV pantoprazole should be administered as a slow injection or infusion. * The IV formulation may be reconstituted and further diluted for infusion. * While generally well-tolerated, long-term PPI use is associated with potential risks. Consider the shortest duration of therapy needed for the condition being treated. * Patients should be advised to report any new or worsening symptoms, including severe diarrhea, muscle cramps, or abnormal heart rhythms. *** **Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information or other authoritative sources before making clinical decisions.